Brief: Xvivo Perfusion Q1 Adj. EBITDA Up At SEK 15.4 Mln
April 25 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* Q1 ADJUSTED EBITDA SEK 15.4 MILLION VERSUS PROFIT SEK 6.3 MILLION YEAR AGO
* Q1 NET SALES SEK 92.7 MILLION VERSUS SEK 58.3 MILLION YEAR AGO
Source text for Eikon: ID:nMFN3dw2Ns
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength